Literature DB >> 21787113

The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.

Erika J Lapinskas1, Suzanne Svobodova, Ian D Davis, Jonathan Cebon, Paul J Hertzog, Melanie A Pritchard.   

Abstract

Renal cell carcinoma is an important clinical disease with poorly understood etiology. ELF5 is an epithelial-specific member of the Ets family of transcription factors, characterized by the 80 amino acid Ets domain that binds the purine-rich GGAA/T Ets motif found in the promoter regions of a variety of genes. Since ELF5 is highly expressed in kidney and has been postulated to function as a tumor suppressor, at least in the context of the breast, we investigated its role in kidney cancer. In renal cell carcinoma ELF5 expression was consistently decreased in tumor samples versus normal. ELF5 mRNA was decreased in 94% of lesions tested and ELF5 protein was undetectable in 40/40 kidney-derived carcinomas. Re-expression of the ELF5 gene in 786-O renal carcinoma cells suppressed their tumorigenic capacity in vitro and in vivo. This work is the first to suggest that ELF5 has tumor suppressor activity in the kidney.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21787113     DOI: 10.1375/twin.14.4.316

Source DB:  PubMed          Journal:  Twin Res Hum Genet        ISSN: 1832-4274            Impact factor:   1.587


  7 in total

1.  Characterization of Associated Nonclassical Phenotypes in Patients with Deletion in the WAGR Region Identified by Chromosomal Microarray: New Insights and Literature Review.

Authors:  Vanessa Sodré de Souza; Gabriela Corassa Rodrigues da Cunha; Beatriz R Versiani; Claudiner Pereira de Oliveira; Maria Teresa Alves Silva Rosa; Silviene F de Oliveira; Patricia N Moretti; Juliana F Mazzeu; Aline Pic-Taylor
Journal:  Mol Syndromol       Date:  2022-02-11

2.  ELF5 inhibits the proliferation and invasion of breast cancer cells by regulating CD24.

Authors:  Xinjian Qu; Qianqian Li; Simei Tu; Xiaocheng Yang; Wen Wen
Journal:  Mol Biol Rep       Date:  2021-06-19       Impact factor: 2.316

3.  ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.

Authors:  Hongchao Yan; Linglin Qiu; Xiaolei Xie; He Yang; Yongli Liu; Xiaoman Lin; Hongxiang Huang
Journal:  Oncol Rep       Date:  2017-02-02       Impact factor: 3.906

4.  Icariin attenuates endothelial-mesenchymal transition via H19/miR-148b-3p/ELF5 in ox-LDL-stimulated HUVECs.

Authors:  Shan Liu; Dong-Sheng Xu; Min Li; Yang Zhang; Qi Li; Teng-Teng Li; Li-Qun Ren
Journal:  Mol Ther Nucleic Acids       Date:  2020-12-03       Impact factor: 8.886

5.  ELF5 isoform expression is tissue-specific and significantly altered in cancer.

Authors:  Catherine L Piggin; Daniel L Roden; David Gallego-Ortega; Heather J Lee; Samantha R Oakes; Christopher J Ormandy
Journal:  Breast Cancer Res       Date:  2016-01-07       Impact factor: 6.466

Review 6.  ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.

Authors:  Ian Y Luk; Camilla M Reehorst; John M Mariadason
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

7.  Expression and clinical significance of WWOX, Elf5, Snail1 and EMT related factors in epithelial ovarian cancer.

Authors:  Yakun Hu; Yuchen Yan; Yang Xu; He Yang; Lisha Fang; Yongli Liu; Xin Li; Qiang Li; Hongchao Yan
Journal:  Oncol Lett       Date:  2019-12-12       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.